NCT01114230已完成1 期
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects With Advanced Renal Cell Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 3
- 主要终点
- Safety assessed by recording adverse events, vital signs and laboratory assessments
研究概览
简要总结
The purpose of this dose escalation study is to examine the safety and pharmacokinetics (PK) of AGS-16M8F administered in subjects with advanced renal cell carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic or cytologic diagnosis (recent or remote) of metastatic renal cell carcinoma (including papillary, clear cell, and excluding transitional cell types) that is not amenable to cure by surgery or other means.
- •Non-measurable or measurable disease according to Response Criteria for Solid Tumors (RECIST Version 1.1)
- •Eastern Cooperative Group (ECOG) performance status of 0-1
- •Negative pregnancy test (women of childbearing potential)
- •Hematologic function, as follows:
- •Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- •Platelet count ≥ 100 x 109/L
- •Hemoglobin ≥ 9 g/dL (transfusions are allowed)
- •Renal function, as follows:
- •creatinine ≤ 1.5 x upper limit of normal (ULN), or calculated glomerular filtration rate (GFR) > 50 mL/min if creatinine > 1.5x ULN
- •Hepatic function, as follows:
- •Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN or ≤ 5x ULN if known liver metastases
- •Total bilirubin ≤ 1.5 x ULN
- •International Normalized Ratio (INR) < 1.3 (or ≤ 3.0 if on therapeutic anticoagulation)
- •Women and men of childbearing potential must be advised and agree to practice effective methods of contraception during the course of the study and for four weeks after the last AGS-16M8F infusion administration
排除标准
- •Past or present documented central nervous system (CNS) tumor or CNS metastasis
- •Use of any investigational drug (including marketed drugs not approved for this indication) within 4 weeks prior to screening
- •History of thromboembolic events and bleeding disorders ≤ 3 months (e.g., DVT or PE)
- •Active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 12 months of study enrollment, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrythmias not controlled by outpatient medication
- •Major surgery (that requires general anesthesia) within 4 weeks of study enrollment
- •Women who are pregnant (confirmed by positive pregnancy test) or lactating
- •Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B surface antigen
- •Active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of screening
研究组 & 干预措施
Dose Level 1
Experimental
干预措施: AGS-16M8F (Drug)
Dose Level 2
Experimental
干预措施: AGS-16M8F (Drug)
Dose Level 3
Experimental
干预措施: AGS-16M8F (Drug)
Dose Level 4
Experimental
干预措施: AGS-16M8F (Drug)
Dose Level 5
Experimental
干预措施: AGS-16M8F (Drug)
Dose Level 6
Experimental
干预措施: AGS-16M8F (Drug)
Dose Level 7
Experimental
干预措施: AGS-16M8F (Drug)
Dose Level 8
Experimental
干预措施: AGS-16M8F (Drug)
Dose Level 9
Experimental
干预措施: AGS-16M8F (Drug)
结局指标
主要结局
Safety assessed by recording adverse events, vital signs and laboratory assessments
时间窗: For 12 weeks during treatment period and up to 4 weeks follow up
Pharmacokinetic variables assessment through analysis of blood samples
时间窗: Up to day 15 for cycle 1 and cycle 4 and pre-dose for cycles 2 and 3; every 3 weeks during the second 12 weeks of treatment; and if subject continues on study drug, every 12 weeks thereafter
次要结局
- Incidence of anti-AGS-16M8F antibody formation(Baseline; up to day 64 during the first 12 weeks; and if subject continues on study drug, every 3 weeks during the second 12 weeks of treatment and every 12 weeks thereafter)
- Incidence of Tumor Response (complete or partial response)(Baseline and every 12 weeks while on study drug)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
MGD009/MGA012 Combination in Relapsed/Refractory CancerAdvanced Solid TumorsNCT03406949MacroGenics25
已完成
1 期
A Safety Study of SGN-CD19A for B-Cell LymphomaBurkitt LymphomaLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellPrecursor B-cell Lymphoblastic Leukemia-LymphomaNCT01786135Seagen Inc.64
已完成
1 期
A Safety Study of SGN-CD19A for Leukemia and LymphomaBurkitt LymphomaPrecursor B-cell Lymphoblastic Leukemia-LymphomaNCT01786096Seagen Inc.92
撤回
1 期
Study of Select Combinations in Adults With MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera MyelofibrosisMyelofibrosisPrimary MyelofibrosisPMFNCT04283526Novartis Pharmaceuticals
已完成
1 期
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic CancerMetastatic Pancreatic CancerNCT02734160Eli Lilly and Company37